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Abstract
Background: Chronic kidney disease (CKD) amounts to a heavy burden for health services. There is no long-running
epidemiological tool for CKD before dialysis. We here present the protocol for a cohort of patients with “non-dialysis”
CKD receiving care in the Bourgogne-Franche-Comté region of France. The aim of this cohort was to periodically
describe the characteristics of patients included and their care provision, to analyse evolution in care and patients’
kidney function outcomes.
Methods: The ND-CRIS cohort is prevalent and incident. Patients are included in the cohort if over 18, with a
glomerula filtration rate (GFR) <60 ml/min/1.73 m2, non-dialysed, informed on the research and not having
opposed it, and followed by a nephrologist in one of the 9 centres in the region, (3 pilot centres joined by
6 others in 2015). All the patients are followed up, with varying time lapses according to the degree of GFR
deterioration. Data is collected by clinical research assistants (CRAs) using a dedicated computerised case-report
form (CRF). Professional practices are assessed using indicators defined by the French Health Authority. The
follow-up of patients included should enable assessment of the evolution of their GFR and co-morbidities.
The periodic descriptions should give insight into evolution in epidemiological terms.
Discussion: The ND-CRIS meets a need in epidemiological tools in France for CKD. The cohort does claim to
be representative, of ND-CKD patients receiving care from nephrologists. The open and incident nature of the
cohort and the number of patients included in the ND-CRIS should provide answers to questions that cannot
be answered by smaller solely prevalent cohorts. The numbers of patients included over the study period
(2391 patients in 3 centres in 3 years) suggests that the figure of 5000 patients should be reached by 2017. The
participation of nephrologists and the rate of inclusions point to the feasibility of the implementation of this
cohort. Beyond the information to be found in the CRFs, this cohort should also enable ad hoc studies, in
particular in the area of pharmaco-epidemiology, and it could later serve as a research platform and as a public
health surveillance tool.
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Background
Chronic kidney disease (CKD) or renal insufficiency
(CRI) is a growing burden for health services [1]. It af-
fects 10 % of the adult population in Western countries
such as the USA [2]. In France, the data is sparse and
fragmented, derived from studies on high-risk popula-
tions and one prospective study running from 2004 to
2006 in the Nancy urban area (EPIRAN) which enabled
an estimation of the annual incidence of CKD in the
general population as being 1/1000 (1.3/1000 among
men and 0.7/1000 among women) [3]. According to the
French health authority (HAS) the prevalence of CKD in
France is around 3 million adults, or about 10 % of the
adult French population, with around 70 000 cases of
ESRD (end-stage renal disease) [4].
A large body of recent data has altered the way CKD is
viewed and managed, which has led to an updating of
guidelines – KDIGO 2012, NICE 2008, 2014 [5–7].
Resorting to replacement systems (dialysis or renal trans-
plant) is a major turning-point in the illness. This is why
the so-called “end-stage” forms (ESRD) during which pa-
tients need to resort to renal replacement systems, are dis-
tinguished from less advanced forms, which precede these
final resorts, and which are referred to as “non-dialysis”
chronic kidney disease (ND-CKD). Numerous profes-
sionals are involved in the care and management of CKD,
and in the early stages specialised nephrologists are not al-
ways involved. Further to this, the indicators required to
refer a ND-CKD patient to a nephrologist (albuminuria
and/or fall in GFR) are still in debate.
In France as in other countries, for a long time the so-
called “end-stage” phase of the illness focused the atten-
tion of the health authorities on account of its weight in
terms of morbidity, mortality and quality-of-life, and also
on account of the cost of care, linked in particular to
dialysis. Today, however, considerable interest has been
aroused in ND-CKD on account of its increasing weight
in public health, linked to the ageing of the general
population and the increase in frequency of its main de-
terminants, in particular diabetes and hypertension. This
focus is all the more relevant because optimal care
provision in the early stages of kidney disease can con-
tribute to delaying the deterioration in kidney function,
and can even avoid the need to resort to renal replace-
ment therapies.
In 2004, the Agence Nationale d’Accréditation et d’E-
valuation des Soins (ANAES) (then the French national
agency for accreditation and evaluation of care) issued
recommendations for slowing the progression of chronic
kidney disease in adults [8]. At present, legislation by
the French parliament is in debate concerning the
implementation of pilot projects for coordinating the
health itineraries of patients in the area of chronic diseases
such as CKD [9].
Although since 2002 regular epidemiological data has
been available on ESRD, with the REIN registry [10] and
soon data from the large national prevalent cohort for ND-
CKD (the CDK-REIN cohort) [11] and the NEPHROTEST
cohort [12], there is in France no long-running epidemio-
logical data system for ND-CKD, and the epidemiology of
CKD is as yet not well mapped out.
With an already formed network of hospital nephrolo-
gistsa managing ESRD patients undergoing dialysis as well
as patients before dialysis in the Bourgogne-Franche-
Comté region of France, and with a funding from the Foun-
dation Transplantation, we have been able to form a cohort
of patients with chronic kidney disease before dialysis (the
Non-Dialysis Chronic Renal Insufficiency cohort, ND-
CRIS), for which the protocol is presented here. The cre-
ation of this ND-CRIS cohort originates from the demand
of nephrologists in this network, who wanted to have regu-
lar data available on the populations they have to manage,
on their own practices, and on the evolution of the popu-
lations that they follow in consultation.
Objectives
The ND-CRIS cohort was designed to meet three main
objectives:
First, to describe the evolution of the incidence/patient
characteristics of ND- CKD patients managed by ne-
phrologists along the time in order to gain knowledge
on the epidemiological evolution of CKD in France.
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Secondly, to describe the quality of the management
of the CKD patients included in the cohort, related to
the ANAES/HAS indicators. Alongside, the ND-CRIS
cohort should also provide regular data on therapeutic
management (in particular prescription of medication),
and on the biological examinations prescribed by the
practitioners in the centres.
Finally, to map the slopes for deterioration in renal
function over time, to describe the evolution of patients
included up to the time of any recourse to renal replace-
ment therapies, with a specific description of patients
reaching the “end-stage”, and to determine the risk factors
related to patterns of evolution.
To enable analysis of the quality of care management,
among the 10 indicators recommended by ANAES [8]
we chose five that that are readily accessible since they
are collected in the CRFs, and another that is recom-
mended in the care itinerary guide issued by the HAS
(Haute Autorité de la Santé) [4]. These indicators will
enable the following:
 follow-up of the evolution of blood pressure and
proteinuria means among these patients [8]
 assessment of medication-related iatrogenic
risk via systematic collection and measurement
of the proportions of patients receiving
aminoglycosides, NSAIDs, and iodine
contrasting agents [8]
 assessment of the proportion of patients receiving
renin-angiotensin system antagonists, angiotensin
converting enzyme (ACE) inhibitors, and
angiotensin II receptor antagonists (ARA2) [8]
 assessment of the proportion of diabetic patients
under ARA2 [8]
 assessment of the proportion of patients vaccinated
against hepatitis B from stage 3b in CKD [4]
 quantification of the frequency of follow-up
consultations for patients [8].
Beyond the information available in the CRFs, the ND-
CRIS cohort will also enable ad hoc studies to assess the
risk-benefit ratio of health products and procedures.
In fine, the ND-CRIS cohort should provide a long-
running epidemiological tool in the area of ND-CKD.
Methods/Design
The ND-CRIS is an open, prospective, prevalent, inci-
dent cohort of non-determined duration.
It is implemented in nine nephrology centres in hospi-
tals in the Bourgogne-Franche-Comté region of France,
and implicates 44 investigating physicians, assisted by
five CRA, under the coordination of a project head. The
project as a whole is managed by a steering committee
and an head operational director.
The investigating hospitals are located in Auxerre,
Besançon, Chalon sur Saône, Dijon, Dôle, Mâcon, Mon-
tbéliard, Sens and Vesoul (see Fig. 1). A feasibility or pilot
phase was conducted in three centres (Besançon, Mâcon
and Belfort-Montbéliard) between April 2012 and June
2015. The feasibility of the data collection and the organ-
isation of the work in these facilities was thus explored
and improved. In this period, all eligible patients already
followed up in the centres by nephrologists were included
(prevalent patients) as well as all new patients meeting the
inclusion criteria as they were taken on (incident patients).
So far, the extension phase has enabled eight of the nine
centres in the region to get underway, the 9th being set for
December 2015.
Fig. 1 Geographical situation of the Bourgogne-Franche-Comté investigating centres
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Selection and inclusion of patients
Eligible subjects are those presenting CKD with two GRF
measures <60 ml/min/1.73 m2 calculated by the MDRD
method. This population is stratified according to the oper-
ational definitions of CKD provided by the KDOQI guide-
lines [13] (stages 3 to 5: CKD stage defined as estimated
glomerular filtration rate ≥45 (stage 3a), 30–44 (3b), 15–29
(4), and <15 (5) mL/min/1.73 m2) and non-dialysed. The
population is composed of adults (>18 years) managed by
nephrology teams in the participating centres.
Following information delivered to all eligible subjects,
patients were included in the cohort if the second GFR
measure was still <60 ml/min/1.73 m2, provided they did
not refuse to participate. Patients who had received a trans-
plant or were under dialysis, patients temporarily in one of
the centres but not followed up there, and patients unable
to understand the information sheet were excluded.
Patient follow-up: all patients whose GFR was <60 ml/
min are systematically followed in consultation, with a
frequency mainly dependent upon the degree of deteri-
oration of the GFR and the co-occurrence of proteinuria.
Certain patients with a GFR between 45 and 60 ml/min
and whose condition does not warrant specialist nephol-
ogy care are in general referred to their treating phys-
ician, with instructions to refer them back should their
condition deteriorate, or in case of specific renal
problem.
Data collection and management
The data collection is performed by the 5 CRAs in the
participating centres from medical files. The actual organ-
isation of the data collection in each centre depends on
the internal functioning of each facility. The hospital
manager, the medical information department (DIM) and
the head physician in each department issue the
CRAs with the authorisations required for access to
the medical files in paper and/or electronic form.
The CRAs have the task of identifying the patients
eligible for the cohort on the basis of the coming consulta-
tions by physicians in the centres. The physicians present
the cohort to their patients and refer back to the CRAs to
inform them of any refusals to participate in the cohort.
Information on refusals can be indicated on the consult-
ation report, on the patient’s electronic file, or by other
means chosen by the physician in charge. Once the patient
is informed, and provided he/she has not expressed re-
fusal, the CRA initiates data collection from the medical
file. At each new consultation, the CRA collects the new
data on the consultation and on hospitalisation provided
in the medical file. For patients with GFR <60 ml/min at
inclusion who have not consulted again 18 months later,
the CRA investigates the reasons from the healthcare
teams and, if required, from the person’s birthplace (to as-
certain vital status). Patients are considered lost to follow-
up if this procedure does not enable any information to be
obtained concerning the patient.
The CRAs transfer all relevant information on the
cohort to the medical teams.
The data is collected using an electronic CRF developed
by SLC Expertise. The CRF is created under Microsoft
Access, a relational database management system. Collec-
tion, processing and storage of data complies with ethical
and good epidemiological practice recommendations,
ADELF, ADEREST, AEEMA, EPITER (France 2007) [14]
and with the ISPE Guidelines for Good Pharmaco-
epidemiology Practices (GPP) [15] (Table 1).
Table 1 List of collected data
Data collected At screening At inclusion At follow-up consultations At removal from the cohort
Age /Gender/ « department » socioprofessional status X
Data of consultation X x X
Creatinine levels x x X
Diagnosis of kidney disease X
Risk factors, complications, hospitalisations x X
Clinical examination : weight, stature, blood pressure x X
Biological investigations : proteinuria, microalbuminuria,
calcemia, phosphoremia, hémoglobin, 25 OHD3, PTH,
ferritinemia, iron, saturation, CRF
x x
Investigations, Imagery with contrasting substances x
Medication x x
Date of dialysis, method of dialysis, date of fistula instatement,
patient information
x
Date of transplant, patient information x
Death and cause x
Other reason for removal from the cohort x
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Inclusion potential and activity of centres
One of the objectives of the ND-CRIS cohort is also to
provide the hospitals with information on their patient
number. In January 2015, the estimations of annual
number of patients for this pathology conducted in col-
laboration with heads of nephrology departments were
as follows (Table 2).
Statistical analyses
Patient numbers and characteristics will be described
for the overall cohort, and for each centre. Data ana-
lysis will concern the variables collected, and descrip-
tive statistical analyses will be performed each year
on all variables.
With 5,000 patients, assuming equal groups, an aver-
age follow-up of 5 years, and a censoring rate of 0.1 per
year, the minimum detectable hazard ratios (with two-
sided α = 5 % and 80 % power) for a survival analysis are
1.20, 1.15 and 1.12 for baseline event rates of 0.05, 0.10
and 0.20 per year [12].
Depending on their nature, quantitative variables will
be described by total numbers, numbers of missing data,
numbers of items of data collected, median, mean and
standard deviation, 95 % confidence interval and ex-
treme values (max/min).
Qualitative variables will be described in terms of total
numbers, numbers of missing data, numbers of items of
data collected, percentages for each modality of response
(calculated from completed data alone) and 95 % confi-
dence interval.
The statistical tests will be unilateral and the signifi-
cance threshold is set at 5 %. Inter-group comparisons
will be performed using:
 the Chi2 test or the Fischer exact test if the
theoretical numbers are below 5 for qualitative
variables,
 Student’s test for Gaussian quantitative variables
 Wilcoxon’s non-parametric test for semi-quantitative
or non-Gaussian quantitative variables.
The statistical analyses will be performed on SAS® soft-
ware, version 9.4, SAS Institute, NC, Cary, USA.
The evolution of the main variables will be calculated
on the basis of data from as close as possible to January
1st of year N and year N + 1. In each centre and for the
overall population, patient incidence and prevalence will
be measured. For each category of treatment, the per-
centages of patients currently exposed and previously
exposed will be calculated. The number of pharmaco-
logical treatments prescribed simultaneously will also be
calculated.
The number of consultations will be recorded for each
centre and for the different stages of kidney disease. Bio-
logical parameters, GFR, BMI and blood pressure will be
recorded for the overall population, for the population
in each centre, and for the different stages in kidney dis-
ease (3, 4, or 5).
Likewise, over one year, the percentages of patients
whose GFR improves, stabilises or deteriorates are also
calculated.
The main indicators derived from the cohort are
issued three-monthly to the medical teams. A complete
report presenting all the variables described in the CRFs
will also be sent to the centres once a year. There will be
regular publications of results in scientific journals.
Quality control procedures will be implemented yearly
in each participating centre. This will include a complete
audit of ten randomly-selected medical files.
The data collected via this cohort is indirectly identifi-
able, thus requiring the authorisation of the French ad-
visory committee on information processing in the area
of health (CCTIRS), equivalent to an ethics committee
[16], and of the CNIL (French data protection authority).
The CCTIRS issued approval on July 27th 2015 and the
CNIL on November 26th 2015.
For this cohort, an information sheet is issued to the
patient by the physician.
Discussion
The need to develop epidemiological cohorts in France
has been underlined by the Government and by health
product manufacturers [17]. Their value and function,
and the quality criteria to be met for them to yield tools
for public health monitoring, were described in a docu-
ment issued by InVS in 2010 [18].
The ND-CRIS is a large cohort that complements the
existing epidemiological tools available in France in the
area of kidney disease, in particular the REIN registry
[10] and the CKD-REIN Cohort [12]. It takes its place
among the large international cohorts on CKD, such as
those reviewed in the Chronic Kidney Disease Prognosis
Consortium [19].
While the REIN registry collects national data in
France concerning patients with end-stage renal disease
(ESRD), the ND-CRIS concerns the same population as
the CKD-REIN cohort on regional scale. The size, the
objectives and the methods of these two cohorts differ.
While the CKD-REIN is a closed cohort of prevalent
Table 2 Estimation of CKD patients by centre
Auxerre: 500 patients Besançon: 1,000 patients
Chalon sur Saône: 500 patients Dijon: 1,000 patients
Dôle: 400 patients Mâcon: 800 patients
Montbéliard: 900 patients Sens: 250 patients
Vesoul: 600 patients
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patients (around 3600 expected) aiming for national
representativeness, the ND-CRIS cohort is open and
concerns both prevalent and incident patients.
In the CKD-REIN the patients are to be followed over
5 years, while for the ND-CRIS patient follow-up will be
pursued until death or until the instatement of renal
replacement therapy.
Finally, while the main aim of the CKD-REIN is to
identify risk factors and markers for the progression of
chronic kidney disease from a defined sample, the aim of
the ND-CRIS is to provide an on-going epidemiological
tool to gain knowledge on epidemiological trends, and
evolution in the quality of care management for patients
with ND-CKD, as well as to enable ad hoc studies on
various subjects of interest. Because it seeks to address
research questions that differ from those of the CKD-
REIN cohort, the ND-CRIS cohort widens the field of
research in the area of chronic kidney disease.
The ND-CRIS cohort has several strengths. The type
of cohort – open, incident/prevalent and without a time
limit – means it is expected to provide answers to ques-
tions that closed cohorts cannot address, in particular
because of their lack of temporal representativeness. The
participation of nephrologists across the Bourgogne-
Franche-Comté region ensures territorial representative-
ness for CKD patients cared for by a nephrologist. It
could thus provide a tool for regional public health pol-
icies. It will also have temporal relevance.
The results of a pilot study conducted in three of the
nine nephrology centres, which are to be published, have
demonstrated the feasibility of the ND-CRIS cohort, meet-
ing adequate quality requirements. At present 8 of the
nine centres have started up, and all will be underway in
February 2016. 2391 patients have been included and their
follow-up has been initiated. The number of patients that
can be reasonably expected given the turnover of patients
followed by the nephrologists concerned (at least 5000 pa-
tients by 2017), in addition to providing routine descrip-
tive data from the CRFs, will also enable ad hoc studies.
The ND-CRIS cohort also has certain limitations. As
indicated earlier, the ND-CRIS does not a priori claim
national representativeness. The management of patients
with kidney disease varies from country to country and
region to region. Thus the regional character of the ND-
CRIS will preclude any extrapolation of the data, which
will be considered as dependent on the region or on the
care management implemented. The confrontation of
the characteristics of the ND-CRIS patients with those
in the CKD-REIN cohort could however provide infor-
mation on the degree of national representativeness of
the ND-CRIS cohort.
The ND-CRIS is not representative either of all ND-
CKD patients. Indeed, screening and follow-up of patients
in the early stages of the disease are generally managed by
GPs or other specialists (diabetologist, cardiologist …).
The ND-CRIS does however aim to be representative of
ND-CKD patients managed by nephrologists, who accord-
ing to HAS recommendations [4] should correspond to a
ND-CKD population with a creatinine clearance of
<45 ml/min, and a population with a clearance between
45 and 60 ml/min in case of rapidly progressing or com-
plicated forms, or in case of doubt as to the nature of the
renal disease.
Although the CKD-EPI calculator has shown better per-
formances in classifying and predicting evolution in kid-
ney disease, in particular for GFRs between 45 and 59 ml/
mn [19], and for threshold values around 60 ml/mn, the
MDRD has been chosen because it is the most widely
used by nephrologists in the region, and is the equation at
present recommended by HAS. In addition, as classifica-
tion errors generally lead to a reclassification of lesser se-
verity of impairment of renal function, the MDRD does
not lose CKD screening ability. The conversion of MDRD
values to CKD-EPI values will however be performed a
posteriori. Cystatin C titration, however, since it is not cov-
ered by health insurance reimbursements, cannot be used.
Like all cohorts with long-term follow-up, one of the
most problematic limitations is the number of subjects
lost to follow-up. Although unavoidable, loss to follow-up
cannot be precisely estimated over the years, but it could
be reduced by the CRAs referring back to the nephro-
logists, and if need be to the place of birth of missing
subjects to ascertain vital status.
Finally, at the present stage, the ND-CRIS does not yet
have a biobank as does the CKD-REIN. The nature of
the ND-CRIS cohort and its scale mean that it would be
difficult to collect and store samples. In addition, the
immediate objectives of the ND-CRIS differ from those
of the CKD-REIN, and do not in fact require a system of
this sort. It would nevertheless be possible to envisage
the creation of a biobank in an ancillary protocol.
For the moment, the ND-CRIS cohort will provide
nephrologists with regular data on the epidemiology of
the population they are managing, and on their own
practices. Each participating centre will receive the data
on its own practices, but only aggregated data will be
used in communications and publications. With the
follow-up of included patients, the routine data contained
in the CRFs will enable the trends in the characteristics of
the population managed for ND-CRIS to be documented,
and also, allowing for an adequate time-lapse, the impact
of management on renal function, on complications and
on recourse to renal replacement therapies.
The ND-CRIS can already afford scope for ad hoc
studies on subjects of interest, such as pharmaceutical
products or other health products.
Pharmaco-epidemiological studies are among the issues
that require urgent attention on account of their scale.
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Indeed, the CKD population is vulnerable – a vulnerability
correlated overall with the degree of deterioration in renal
function – and exposed to numerous medications, which
increases iatrogenic medication-related risk. In addition,
the risk-benefit ratio of health products used among these
patients is not well known, in particular in the moderate
to severe stages of kidney disease, as they are often ex-
cluded, or not well represented, in trials. Thus the product
summaries of numerous medications include a mention of
particular caution required without any real evidence to
back it up, so that the prescription of such substances is
fraught with uncertainty. With the exception of medica-
tions with restricted indications, the large size of the co-
hort and the degree of exposure to a wide range of
medications should in many cases enable experimental ap-
proaches to provide answers to questions on medication
administered to subjects with kidney disease.
The ND-CRIS cohort should lead on to further studies
and developments. We are already planned a study of
patient care itineraries so as to identify barriers to optimal
care in reference to health authority guidelines [4].
Finally, the ND-CRIS cohort, as an on-going epidemio-
logical tool, could broaden its objectives to the surveillance
of health safety issues.
Acknowledgements
We would like to thank Professor Marcel Golberg for his advice and the
Foundation Transplantation for its financial support.
Funding
The ND-CRIS cohort study receives a grant exclusively from the Foundation
Transplantation.
Availability of data and material
At the time of the protocol elaboration, no data was generated.
Authors’ contributions
JM participated in the initiation and coordination of the cohort and its
design, and drafted the manuscript. GJ participated in the initiation and
coordination of the cohort, and the design. CB coordinates the CRAs,
in collaboration with the participating hospitals. CG ensures the data
management and performs the statistical analyses. GSCD participated in the
initiation and coordination of the cohort and the design. JMC participated in
the initiation and coordination of the cohort, and its design. All authors have
reviewed the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The protocol has been successively approved by the Advisory Committee for
Data Processing in Health Research at the Research French Ministry (CCTIRS:
Comité Consultatif sur le Traitement de l’Information en matière de
Recherche dans le domaine de la Santé) which is equivalent to an Ethics
Committee, (Dossier n°15.277 bis: positive opinion (avis favorable) on July
16th, 2015) and by the French data protection authority (CNIL: Commission
Nationale de l’Informatique et des Libertés) : notification of authorisation
(notification d’autorisation) n° 915467 on November 24th, 2015.
aInvestigating physicians
CH de Mâcon: Jean-Simon Virot, Hamid Nefti, Anne-Claire du Besset, Alim
Heyani, Anna Filancia, Gérard Janin
CHRU de Besançon: Jean-Marc Chalopin, Didier Ducloux, Jamal Bamoulid,
Cécile Courivaud, Catherine Bresson-Vautrin, Nadège Devillard, Maria Yannaraki,
Frank Marechal, Barbara Nollet, Thomas Crepin, Caroline Roubiou
CH de Belfort-Montbéliard: Claude Bernard, Véronique Fournier, Helena
Marcu, Antoine. Nicolas, Nathalie Rogeboz, Nihel Skandrani, Pierre Vautrin
CH de Vesoul: Karim Khellaf, Adelina Florea, Hélène Phillipot, Mohammed
Bemmerzouk
CH de Dôle: Gérard Motte, Delphine Henriet-Viprey, Patricia Lemarchand
CH de Chalon sur Saône: Philippe Dubot, Jamal Yazji, Adel Sahar, Julien
Journet, Abdelkader Bemrah, Ayman Abokasem
CH d’Auxerre: Benoît Jonon, Rachid Bourouma, Houssem Eddine Berrabah et
Soraya Agha-Mir
CH de Sens: Philippe Michel, Mohammed Hammadi, Alain Frejate
CRAs: Cindy Claudon, Blandine Firek, Julie Gucciardi. Louise Mark, Caroline Savet
In charge of data collection: Sandrine Lombion
CRA coordinator, project head: Camille Bachot
Biostatistician, Data-Manager: Christophe Gousset
Operational head: Geoffroy Sainte-Claire Deville
Steering committee: Dr Gérard Janin, Pr Jean-Marc Chalopin, Pr Jacques Massol
Author details
1Institut PHISQUARE, 20, rue Saint Saëns, 75015 Paris, France. 2Centre
Hospitalier de Mâcon, 350, boulevard Escande, 71018 Mâcon Cedex, France.
3Department of Nephrology, CHRU de Besançon, Hôpital Jean Minjoz, 3,
boulevard Alexandre Fleming, 25030 Besançon, France.
Received: 3 February 2016 Accepted: 22 June 2016
References
1. Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C.
High burden and unmet patient needs in chronic kidney disease.
Int J Nephrol Renov Dis. 2012;5:151–63. doi:10.2147/IJNRD.S37766. PubMed
PMID: 23293534, PubMed Central PMCID: PMC3534533, Epub 2012 Dec 13.
2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic
kidney disease and decreased kidney function in the adult US population:
Third National Health and Nutrition Examination Survey. Am J Kidney Dis.
2003;41(1):1–12. PubMed PMID: 12500213.
3. Loos-Ayav C, Briançon S, Frimat L, André JL, Kessler M, pour le comité de
pilotage EPIRAN. [Incidence of chronic kidney disease in general
population,EPIRAN study]. Nephrol Ther. 2009;5 Suppl 4:S250–5.
doi:10.1016/S1769-7255(09)74554-7. French.
4. Haute Autorité de Santé, Guide du parcours de soin. Maladie rénale
chronique de l’adulte. Février 2012.: consulté le 15 novembre 2015,
disponible sur le site. (http://www.has-sante.fr/portail/upload/docs/
application/pdf/2012-04/guide_parcours_de_soins_mrc_web.pdf). Accessed
19 Jul 2016.
5. Kidney Disease : Improving Global Outcomes (KDIGO), Clinical Practice
Guideline for the Evaluation and Management of Chronic Kidney Disease
Kidney International Supplements (2013) 3, 136–150. (http://www.kdigo.org/
clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf). Accessed
19 Jul 2016.
6. National Institute for Health and Clinical Excellence. Chronic kidney disease.
Early identification and management of chronic kidney disease in adults in
primary and secondary care. London: NHS; 2008. https://www.nice.org.uk/
guidance/cg73?unlid=363006463201662925636. Accessed 20 Jul 2016.
7. National Institute for Health and Clinical Excellence. Chronic kidney disease
(partial update) Early identification and management of chronic kidney
disease in adults in primary and secondary care. Clinical Guideline 182.
Consulté le 15 novembre 2015, disponible sur le site https://www.nice.org.
uk/guidance/cg182. Methods, evidence and recommendations July 2014.
Accessed 19 Jul 2016.
8. ANAES. Septembre 2004. Moyens thérapeutiques pour ralentir la
progression de l’insuffisance rénale chronique chez l’adulte.
Recommandations pour la pratique clinique. (consulté le 15 novembre
2015, disponible sur le site http://www.has-sante.fr/portail/upload/docs/
application/pdf/IRC_2006_rap.pdf). Accessed 20 Jul 2016.
Massol et al. BMC Nephrology  (2016) 17:92 Page 7 of 8
9. France, Projet de Loi de modernisation de notre système de santé, 2015
(consultéle 20 novembre 2015 sur le site : http://www.AssembléeNationale.
fr/14/projets/p12302.asp-art22, chp IV).
10. Couchoud C, Stengel B, Landais P, Aldigier JC, de Cornelissen F, Dabot C,
Maheut H, Joyeux V, Kessler M, Labeeuw M, Isnard H, Jacquelinet C. The
renal epidemiology and information network (REIN): a new registry for
end-stage renal disease in France. Nephrol Dial Transplant. 2006;21(2):411–8.
Epub 2005 Oct 18.
11. Stengel B, Combe C, Jacquelinet C, Briançon S, Fouque D, Laville M,
Frimat L, Pascal C, Herpe YE, Deleuze JF, Schanstra J, Pisoni RL, Robinson
BM, Massy ZA. The French Chronic Kidney Disease-Renal Epidemiology and
Information Network(CKD-REIN) cohort study. Nephrol Dial Transplant. 2014;
29(8):1500–7. doi:10.1093/ndt/gft388. PubMed PMID: 24064325, PubMed
Central PMCID: PMC4106639, Epub 2013 Sep 24.
12. Boucquemont J, Metzger M, Combe C, Stengel B, Leffondre K, NephroTest
Study Group. Should we use standard survival models or the illness-death
model for interval-censored data to investigate risk factors of chronic kidney
disease progression? PLoS One. 2014;9(12):e114839.
13. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease : Evaluation,
Classification and Stratification. Am J Dis 39:S1-S266, 2002 (suppl1, Nephrol
Dial Transplant. 2014; 29(8): 1500-7. Doi: 10.1093:ndt/gft388. Epub 2013 Sep 24.
14. Association des Epidémiologistes de Langue Française (ADELF), Association
pour le Développement des Etudes et Recherches en Epidémiologie sur la
Santé au Travail (ADEREST), Association pour l’étude de l’Epidémiologie des
Maladies Animales (AEEMA), et al. Recommandations de déontologie et
bonnes pratiques en épidémiologie [Recommendations for professional
standards and good epidemiological practices]. 2007. Consulté le 15
novembre 2015 sur le site: http://www.constances.fr/espace-scientifique/
base-documentaire-doc.php?d=118. Accessed 19 Jul 2016.
15. International Society for Pharmacoepidemiology (ISPE). Guidelines for Good
Pharmacoepidemiology Practices (GPP).2007. https://www.pharmacoepi.org/
resources/guidelines_08027.cfm. Accessed 20 Jul 2016.
16. Bonaïti-Pellié C, Arveux P, Billette De Villemeur A, Dantchev N, Elbaz A,
Fabre-Guillevin E, Fresson J, Saura C, Saurel-Cubizolles MJ, Serre JL, Simon D,
Stucker I, Thélot B, Tubert-Bitter P, Zureik M. [Treatment of information on
personal health data for research purposes: nobody should ignore the law].
Med Sci (Paris). 2009;25(1):93–7. doi:10.1051/medsci/200925193. French.
17. Présidence de la République, 26 octobre 2009, Rapport du Conseil
Stratégique des Industries de Santé, CSIS N°4; consulté le 20 novembre
2015 sur le site : http://www.orpha.net/actor/Orphanews/2009/doc/CSIS.pdf.
Accessed 20 Jul 2016.
18. Georges Salines, Catherine De Launay. Les cohortes : intérêt, rôle et position de
l’InVS. Saint-Maurice (Fra) : Institut de veille sanitaire, janvier 2010,
2 p. Consulté le 20 novembre 2015 sur le site. (http://www.invs.sante.fr/
publications/2010/cohortes/plaquette_cohortes_fr.pdf). Accessed 20 Jul 2016.
19. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH,
Polkinghorne KR, Shankar A, Smith DH, Tonelli M, Warnock DG, Wen CP,
Coresh J, Gansevoort RT, Hemmelgarn BR, Levey AS, Chronic Kidney Disease
Prognosis Consortium. Comparison of risk prediction using the CKD-EPI
equation and the MDRD study equation for estimated glomerular filtration
rate. JAMA. 2012;307(18):1941–51.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Massol et al. BMC Nephrology  (2016) 17:92 Page 8 of 8
